ClinicalTrials.gg
RecruitingNCT06918964TAVANS-ICHUpdated Jan 15, 2026

TaVNS for Acute Intracerebral Hemorrhage

An interventional study of transcutaneous auricular vagus nerve stimulation device and Sham device in Intracerebral Hemorrhage, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital — 14 open to participants now, 15 under way, 3 of them phase 3. Cerebral Hemorrhage · Beijing Tiantan Hospital.

Planned enrollment
9th of 15
186 · median 240
Started
2025
with 3 others
No phase
6 of 22
4 open now
Primary completion
2028-06
later than 8 of 14 live
Registered
15th of 22
by date

Among the 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2025, is one of 6 with no phase, reaches primary completion later than 8 of the 14 other live ones, and was the 15th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

14 of the 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with acute intracerebral hemorrhage (ICH). The taVNS intervention will be delivered using the BS-TVNS800-1 transcutaneous electrical stimulation therapy device (KERFUN, Shanxi, China). A total of 186 patients will be randomly assigned in a 1:1 ratio to either the taVNS group or the sham-taVNS group. The primary outcome is the relative volume of perihematoma edema assessed on day 10-14 after randomization. Adverse events associated with taVNS therapy will be systematically evaluated to assess its safety profile.

03

Conditions studied

  • Intracerebral Hemorrhage

Keywords

  • Intracerebral Hemorrhage
  • taVNS
  • perihemtomal edema
  • neuroinflammation
  • secondary brain injury
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with spontaneous supratentorial intracerebral hemorrhage.
  2. Age between 18 and 80 years.
  3. Onset within 72 hours.
  4. Hematoma volume between 5 and 40 mL.
  5. Glasgow Coma Scale (GCS) score greater than 8.
  6. Written obtained from the patient or their legal representative.

Exclusion criteria

Exclusion Criteria:

  1. Secondary intracerebral hemorrhage (e.g., traumatic, tumor-related, vascular malformation, aneurysm, or coagulopathy-related).
  2. Primary intraventricular hemorrhage.
  3. Parenchymal hemorrhage that ruptures into the ventricles, with blood completely filling one lateral ventricle, the third ventricle, the fourth ventricle or more than half of both lateral ventricles.
  4. Progressive neurological or other severe diseases.
  5. Planned surgical treatment within 24 hours.
  6. Pre-existing disability caused by previous illnesses: Modified Rankin Scale (mRS) score ≥ 3.
  7. Patients with severe cardiomyopathy, heart failure, pacemaker implantation, atrial fibrillation, frequent premature beats, second-degree or higher atrioventricular block, or other severe arrhythmias.
  8. Severe pulmonary disease, liver disease, renal insufficiency ( \< 30 mL/min), active gastrointestinal bleeding, or malignant tumors with an expected survival of less than 3 months.
  9. Patients with hyperthyroidism, hypothyroidism, syncope, epilepsy, multiple sclerosis, Parkinson's disease, multiple system atrophy, or other known disorders affecting autonomic nervous function.
  10. Use of medications that interfere with autonomic function (e.g., beta-blockers, theophylline, tricyclic antidepressants, or ) within 7 days before screening.
  11. Patients who cannot tolerate taVNS.
  12. Congenital or acquired ear abnormalities preventing taVNS treatment.
  13. Inability to comply with 10 days of treatment.
  14. Pregnancy or within 30 days of delivery.
  15. Participation in another interventional clinical trial.
  16. Inability to obtain written from the participant or their legal representative.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
186 participants (estimated)

Study arms

  • Active comparator
    taVNS intervention

    Patients will receive taVNS therapy twice daily for 10 consecutive days, in addition to receiving guideline-adherent conventional treatment during hospitalization.

    Device: transcutaneous auricular vagus nerve stimulation device

  • Sham comparator
    Sham taVNS intervention

    Patients will receive sham taVNS twice daily for 10 consecutive days, in addition to receiving guideline-adherent conventional treatment during their hospital stay.

    Device: Sham device

Interventions

  • Devicetranscutaneous auricular vagus nerve stimulation device

    Place the stimulation device on the left auricle and set the stimulation parameters according to the following conditions: a. Waveform: biphase, square wave; b. Wave width: 200 μs; c. Frequency: Alternating between low frequency (4 Hz for 4 s), high frequency (40 Hz for 8 s), and a 4 s pause; d. Intensity: The maximum intensity that induces the strongest sensation the individual can tolerate without causing pain, usually 1.5-3.5 mA; e. Treatment duration: Each treatment lasted 30 minutes, twice daily (8:00, 16:00) for 10 days.

  • DeviceSham device

    The sham taVNS group received the same parameters with a current intensity of 0.06 mA.

06

What researchers measure

Primary outcomes

  1. Volume of perihematoma edema assessed by CT

    Relative edema volume.

    Time frame: Day 10-14 after randomization

Secondary outcomes

  1. Autonomic activity assessed by heart rate variability

    Heart rate variability (HRV) will be assessed using a 10-minute electrocardiogram (ECG) recorded with a 12-lead ECG Holter (TeleECG BI 12E, Biomedical Instruments Co., Ltd., Shenzhen). HRV indices will be analyzed in both the time domain (e.g., SDNN, RMSSD) and the frequency domain (e.g., LF, HF, LF/HF).

    Time frame: Day 10-14 after randomization

  2. Autonomic activity assessed by baroreflex sensitivity

    Baroreflex sensitivity (BRS) will be evaluated by noninvasively measuring beat-to-beat signals for 10 min using a servo-controlled plethysmograph (FMS-8A, Delica Medical Equipment Co., Ltd., Shenzhen) placed on the middle finger.

    Time frame: Day 10-14 after randomization

  3. National Institutes of Health stroke scale (NIHSS)

    NIHSS is used to assess the severity of functional impairment caused by stroke. It consists of 11 test items, with a total score ranging from 0 to 42. A higher score indicates a more severe stroke.

    Time frame: Day 10-14 after randomization

  4. GCS (Glasgow Coma Scale)

    The GCS is used to assess the level of consciousness in patients, with the total score ranging from 3 to 15. Lower scores indicate more severe impairment.

    Time frame: Day 10-14 after randomization

  5. MMSE (Mini-Mental State Examination)

    The Mini-Mental State Examination (MMSE) is a widely used cognitive screening tool designed to assess global cognitive function, including orientation, memory, attention, language, and visuospatial skills. Scores range from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Day 10-14 after randomization

  6. MoCA (Montreal Cognitive Assessment)

    The Montreal Cognitive Assessment (MoCA) is another cognitive screening instrument optimized for detecting mild cognitive impairment (MCI) and early dementia. Scores range from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Day 10-14 after randomization

  7. PHQ-9 (Patient Health Questionnaire-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a brief, self-report tool validated for screening and monitoring depression severity. Scores range from 0 to 27, with higher scores reflecting greater symptom severity.

    Time frame: Day 10-14 after randomization

  8. 90-day National Institutes of Health stroke scale (NIHSS)

    NIHSS is used to assess the severity of functional impairment caused by stroke. It consists of 11 test items, with a total score ranging from 0 to 42. A higher score indicates a more severe stroke.

    Time frame: 90 ± 7 days after randomization

  9. 90-day modified Rankin Scale (mRS)

    The mRS is used to measure the degree of disability or dependence after a stroke. The scale ranges from 0 to 6 and higher scores indicate greater functional impairment.

    Time frame: 90 ± 7 days after randomization

  10. 90-day EQ-5D (EuroQol 5-Dimension Questionnaire) score

    The EQ-5D is a standardized instrument used to assess health-related quality of life.

    Time frame: 90 ± 7 days after randomization

  11. 90-day GCS (Glasgow Coma Scale)

    The GCS is used to assess the level of consciousness in patients, with the total score ranging from 3 to 15. Lower scores indicate more severe impairment.

    Time frame: 90 ± 7 days after randomization

  12. 90-day MMSE (Mini-Mental State Examination)

    The Mini-Mental State Examination (MMSE) is a widely used cognitive screening tool designed to assess global cognitive function, including orientation, memory, attention, language, and visuospatial skills. Scores range from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: 90 ± 7 days after randomization

  13. 90-day MoCA (Montreal Cognitive Assessment)

    The Montreal Cognitive Assessment (MoCA) is another cognitive screening instrument optimized for detecting mild cognitive impairment (MCI) and early dementia. Scores range from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: 90 ± 7 days after randomization

  14. 90-day PHQ-9 (Patient Health Questionnaire-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a brief, self-report tool validated for screening and monitoring depression severity. Scores range from 0 to 27, with higher scores reflecting greater symptom severity.

    Time frame: 90 ± 7 days after randomization

Other outcomes

  1. Safety assessment

    Adverse events, serious adverse events, death

    Time frame: In the 10-day treatment period

  2. Perihematomal blood-brain barrier permeability

    Perihematomal blood-brain barrier permeability will be assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI).

    Time frame: Day 5-7 after randomization

  3. Evaluation of glymphatic system

    Impairment of the function of the glymphatic system will be assessed by diffusion kurtosis imaging analysis along the perivascular space (DKI-ALPS).

    Time frame: Day 5-7 after randomization

  4. Assessment of microglial activation

    Microglial activation will be quantified by TSPO-PET/MRI.

    Time frame: Day 7-9 after randomization

  5. Interleukin-1β (IL-1β) level in peripheral blood

    IL-1β: A pro-inflammatory cytokine (measured in pg/mL) that drives fever, neutrophil activation, and autoimmune responses. It will be detected by ELISA.

    Time frame: Day 10-14 after randomization

  6. Interleukin-6 (IL-6)

    IL-6: A pro-inflammatory cytokine (pg/mL) involved in acute-phase protein synthesis and B-cell differentiation, and implicated in infections. It will be detected by ELISA.

    Time frame: Day 10-14 after randomization

  7. Tumor Necrosis Factor-alpha (TNF-α)

    TNF-α is a pro-inflammatory cytokine (pg/mL) which can be detected via ELISA.

    Time frame: Day 10-14 after randomization

  8. Interleukin-4 (IL-4)

    IL-4 is an anti-inflammatory Th2 cytokine (pg/mL) which will be measured by ELISA.

    Time frame: Day 10-14 after randomization

  9. Interleukin-10 (IL-10)

    IL-10 is an anti-inflammatory regulator (pg/mL), which will be quantified via ELISA.

    Time frame: Day 10-14 after randomization

  10. Transforming Growth Factor-beta (TGF-β)

    TGF-β is a multifunctional cytokine (pg/mL) that is involved in regulation of cell growth, differentiation, and apoptosis. It will be detected by ELISA.

    Time frame: Day 10-14 after randomization

  11. Neurofilament light chain (NFL)

    NFL is a non-specific biological marker representing neuronal injury (measured in pg/mL). It will be measured by ELISA.

    Time frame: Day 10-14 after randomization

  12. Monocyte subsets

    Classical (CD14++CD16-) differentiate into macrophages for tissue repair, non-classical (CD14+CD16++) patrol vasculature for surveillance, measured in cells/μL by flow cytometry.

    Time frame: Day 10-14 after randomization

  13. CD4+ T cells

    Coordinate adaptive immunity (helper role, cells/μL) via cytokine secretion and immune activation, assessed by flow cytometry with surface marker staining.

    Time frame: Day 10-14 after randomization

  14. CD8+ T cells

    Mediate cytotoxicity (cells/μL), quantified using flow cytometry.

    Time frame: Day 10-14 after randomization

  15. NK cells

    Innate lymphocytes (cells/μL) detected via flow cytometry.

    Time frame: Day 10-14 after randomization

  16. B cells

    Produce antibodies for humoral immunity (measured in cells/μL), enumerated by flow cytometry (CD19/CD20 markers).

    Time frame: Day 10-14 after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2028, 33 months after the start.

Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 33 months is below that.

Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Apr 9, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06918964
Responsible party
Kaijiang Kang (Principal Investigator, Beijing Tiantan Hospital) — Principal investigator
First posted
Apr 9, 2025
Start date
Sep 15, 2025
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion